TK inhibitor treatment disrupts growth hormone axis: Clinical observations in children with CML and experimental data from a Juvenile Animal Model

Klinische Padiatrie

Volumn 225, Issue 3, 2013, Pages 120-126

  Ulmer, A ^a   Tabea Tauer, J ^a   Glauche, I ^b   Jung, R ^b   Suttorp, Meinolf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

children; CML; growth; growth hormone; imatinib; juvenile rat model

Indexed keywords

BOSUTINIB; DASATINIB; DRINKING WATER; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; CANCER CHEMOTHERAPY; CHILD; CHILD GROWTH; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RAT; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; BENZAMIDES; BODY HEIGHT; BONE DEVELOPMENT; CHILD; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, WISTAR;

EID: 84878387514     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1343483     Document Type: Article

References (44)

1. Anderson L. L., Jeftinija S., Scanes C. G. Growth hormone secretion: molecular and cellular mechanisms and in vivo approaches. Exp Biol Med (Maywood): 2004; 229 291 302 (Pubitemid 38372893)
2. Bansal H. D., Shava U., Varma N. et al. Imatinib Has Adverse Effect on Growth in Children With Chronic Myeloid Leukemia. Pediatr Blood Cancer: 2012; 59 481 484
3. Berman E., Nicolaides M., Maki R. et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med: 2006; 354 2006 2013
4. Boquete H. R., Sobrado P. G., Fideleff H. L. et al. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Clin Endocrinol Metab: 2003; 10 4702 4708 (Pubitemid 37357515)
5. Brooks A. J., Waters M. J. The growth hormone receptor: Mechanism of activation and clinical implications. Nat Rev Endocrinol: 2010; 6 515 525
6. Champagne M. A., Fu C. H., Chang M. et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer: 2011; 57 56 62
7. Deininger M. W., Druker B. J. Specific targeted therapy of chronic myelogenous leukemia with imatinib mesylate. Pharmacol Rev: 2003; 55 401 423 (Pubitemid 37013211)
8. Druker B. J., Guilhot F., O'Brien S. G. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med: 2006; 355 2408 2417 (Pubitemid 44903745)
9. Growth Hormone Research Society Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab: 2000; 85 3990 3993
10. Grunewald TG P., Greulich N., Kontny U. et al. Targeted Therapeutics in Treatment of Children and Young Adults with Solid Tumors: an Expert Survey and Review of the Literature. Klin Padiatr: 2012; 224 124 131
11. Hobernicht S. L., Schweiger B., Zeitler P. et al. Aquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer: 2011; 56 671 673
12. Id Boufker H., Lagneaux L., Najar M. et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer: 2010; 10 298
13. Jaeger BA S., Tauer J. T., Ulmer A. et al. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monoitor: 2012; 18 721 728
14. Kebapcilar L., Bilgir O., Alacacioglu I. et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med Princ Pract: 2009; 18 360 363
15. Keller A., Bierbach U., Mieke J. et al. Ergebnisse einer unizentrischen endokrinologischen Nachsorge onkologischer Patienten im Kindes- und Adoleszentenalter. Klin Padiatr: 2007; 219 333 338 (Pubitemid 350239735)
16. Kimoto T., Inoue M., Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol: 2009; 89 251 252
17. Mariani S., Giona F., Basciani S. et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet: 2008; 372 111 112 (Pubitemid 351958458)
18. Millot F., Baruchel A., Guilhot J. et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French National Phase IV Trial. Blood: 2009; 110 863
19. Millot F., Baruchel A., Guilhot J. et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol: 2011; 29 2827 2832
20. Mignozzi M., Picca S. Chronic myelogenous leukemia following kidney transplantation in a pediatric patient. Pediatr Nephrol: 2001; 16 852 853 (Pubitemid 33040639)
21. Molitch M. E., Clemmons D. R., Malozowski S. et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab: 2006; 91 1621 1634
22. Narayanan K. R., Bansal D., Walia R. et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer: 2013; 10.1002/pbc.24397 [Epub ahead of print]
23. Oliveira M. R., Ohnuma L., Bendit I. et al. Interferon-alpha therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia. Leuk Res: 2001; 25 711 717 (Pubitemid 32492947)
24. O'Sullivan S., Lin J. M., Watson M. et al. The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 2011 49 281 289
25. Pastural E., Takahashi N., Dong W. F. et al. RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines. Oncogene: 2007; 26 1586 1594 (Pubitemid 46398743)
26. Personal communication: in-house reference values; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital, Dresden
27. Quintas-Cardama A., Kantarjian H., Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov: 2007; 6 834 848 (Pubitemid 47500507)
28. Rastogi M. V., Stork L., Druker B. et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer: 2012; 59 840 845
29. Remsing Rix L. L., Rix U., Colinge J. et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia: 2009; 23 477 485
30. Rosenfeld R. G., Belgorosky A., Camacho-Hubner C. et al. Defects in growth hormone receptor signalling. Trends Endocrinol Metab: 2007; 18 134 141 (Pubitemid 46629026)
31. Schmid H., Jaeger B. A., Lohse J. et al. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica: 2009; 94 1171 1179
32. Shima H., Tokuyama M., Tanizawa A. et al. Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia. J Pediatr: 2011; 159 676 681
33. Sorensen P. Tyrosine Kinase Networks in Pediatric Cancer. Klin Padiatr: 2011; 223 45 A2
34. Suttorp M., Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem cell transplantation. Hematology Am Soc Hematol Educ Progr: 2010; 368 376
35. Suttorp M., Yaniv I., Schultz K. R. Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT? Biol Blood Marrow Transplant: 2011; S115 S122
36. Tauer J. T., Hofbauer L. C., König S. et al. Side Effects on the Skeletal System Exerted by Continuous and by Interval Treatment with Tyrosine Kinase Inhibitors in An Animal Model of Juvenile Rodents. Blood: 2011; 118 -A1597
37. Tauer J. T., Hofbauer L. C., König S. et al. Non-selective side effects of non-receptor tyrosine kinase inhibitors (TKI). Klin Padiatr: 2011; 223 - A2
38. Tauer J. T., Ulmer A., Hofbauer L. C. et al. Dasatinib treatment causes alterations in bone metabolism in a juvenile rodent model. Haematologica: 2012; 97 01 67 -A1256
39. Tauer J. T., Hofbauer L. C., Jung R. et al. Impact of continuous release of the tyrosine kinase inhibitor bosutinib via micro-osmotic pump on bone growth in juvenile rats. Med Sci Monit: 2013; submitted
40. Tibullo D., Barbagallo I., Giallongo C. et al. Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematol Oncol: 2012; 30 27 33
41. Ulmer A., Tauer J. T., Suttorp M. Influence of tyrosine kinase inhibitors (TKIs) on endocrinological parameters. Klin Padiatr: 2012; 224 - A4
42. Vandyke K., Fitter S., Dewar A. et al. Dysregulation of bone remodeling by imatinib mesylate. Blood: 2010; 115 766 774
43. Vandyke K., Dewar A. L., Diamond P. et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res: 2010; 25 1759 1770
44. Zadik Z., Estrov Z., Karov Y. et al. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission - a preliminary report. J Pediatr Endocrinol: 1993; 6 79 83 (Pubitemid 23192349)